LLY
NYSEEli Lilly and Company
Healthcare · Drug Manufacturers - General
Why is it down?
no visible trigger- ·From its high of $1,280.34 on 19/08/2026 the price fell 12.0% to $1,137.82.
- ·No clear news driver in the last 10 days.
- ·The market as a whole is calm, so this drop is specific to the company.
- ·Other Drug Manufacturers - General stocks we track are down only 7.5% on average, so this is mostly about the company. See all 13 in this sector →
A drop without a visible trigger is often selling pressure, not new facts. That is the kind of dip the engine looks for, but it is still a guess, not a promise.
Verdict
signal 48 min agoA dip is in progress: 12.0% below its 30-day high, but the fall has not shown a bottom yet. Wait; the verdict turns to Buy when at least 3 of 5 bottom checks pass.
Catalysts
1 h ago- News, last 10 days
- neutral +0.0610 articles
- Next earnings
- 29/10/2026 · in 42 days
- Last report
- 05/08/2026 +27.3% vs estimate
Trade levels
Why the engine says so
History for this ticker
Watch and alert
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease, as well as Strategic partnership with NVIDIA Corporation. The company also has a research collaboration agreement with Insilico Medicine for the development of advance therapies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- Headquarters:
- Indianapolis, United States
- 52-week range:
- $712.05 – $1,292.65
- Website:
- lilly.com
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search